Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Quantitative X-ray computed tomography peritoneography in malignant peritoneal mesothelioma patients receiving intraperitoneal chemotherapy.

Leinwand JC, Zhao B, Guo X, Krishnamoorthy S, Qi J, Graziano JH, Slavkovic VN, Bates GE, Lewin SN, Allendorf JD, Chabot JA, Schwartz LH, Taub RN.

Ann Surg Oncol. 2013 Dec;20 Suppl 3:S553-9. doi: 10.1245/s10434-013-2976-8. Epub 2013 May 24.

2.

Treatment of primary peritoneal mesothelioma by continuous hyperthermic peritoneal perfusion (CHPP).

Park BJ, Alexander HR, Libutti SK, Wu P, Royalty D, Kranda KC, Bartlett DL.

Ann Surg Oncol. 1999 Sep;6(6):582-90.

PMID:
10493628
3.

Repeat cytoreductive surgery and heated intraperitoneal chemotherapy may offer survival benefit for intraperitoneal mesothelioma: a single institution experience.

Wong J, Koch AL, Deneve JL, Fulp W, Tanvetyanon T, Dessureault S.

Ann Surg Oncol. 2014 May;21(5):1480-6. doi: 10.1245/s10434-013-3341-7. Epub 2013 Oct 25.

PMID:
24158467
4.

Multicystic and well-differentiated papillary peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC).

Baratti D, Kusamura S, Nonaka D, Oliva GD, Laterza B, Deraco M.

Ann Surg Oncol. 2007 Oct;14(10):2790-7. Epub 2007 Jul 28.

PMID:
17661150
5.

Diffuse malignant peritoneal mesothelioma: Failure analysis following cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).

Baratti D, Kusamura S, Cabras AD, Dileo P, Laterza B, Deraco M.

Ann Surg Oncol. 2009 Feb;16(2):463-72. doi: 10.1245/s10434-008-0219-1. Epub 2008 Dec 12.

PMID:
19082859
6.

Chemotherapy and serum hyaluronic acid levels in malignant peritoneal mesothelioma.

Hotta T, Taniguchi K, Kobayashi Y, Johata K, Sahara M, Naka T, Tanimura H, Tsubota YT.

Hepatogastroenterology. 2004 Jul-Aug;51(58):1073-83. Review.

PMID:
15239250
8.

Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for malignant peritoneal mesothelioma: mitomycin versus cisplatin.

Blackham AU, Shen P, Stewart JH, Russell GB, Levine EA.

Ann Surg Oncol. 2010 Oct;17(10):2720-7. doi: 10.1245/s10434-010-1080-6. Epub 2010 Apr 27. Erratum in: Ann Surg Oncol. 2011 Dec;18 Suppl 3:S325-6.

PMID:
20422458
9.
10.

Institutional learning curve of cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion for peritoneal malignancies.

Polanco PM, Ding Y, Knox JM, Ramalingam L, Jones H, Hogg ME, Zureikat AH, Holtzman MP, Pingpank J, Ahrendt S, Zeh HJ, Bartlett DL, Choudry HA.

Ann Surg Oncol. 2015 May;22(5):1673-9. doi: 10.1245/s10434-014-4111-x. Epub 2014 Nov 7.

PMID:
25377640
11.

Intraperitoneal chemotherapy for malignant peritoneal mesothelioma.

Vlasveld LT, Gallee MP, Rodenhuis S, Taal BG.

Eur J Cancer. 1991;27(6):732-4. Erratum in: Eur J Cancer 1991;27(12):1717.

PMID:
1829913
12.

Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma.

Alexander HR Jr, Bartlett DL, Pingpank JF, Libutti SK, Royal R, Hughes MS, Holtzman M, Hanna N, Turner K, Beresneva T, Zhu Y.

Surgery. 2013 Jun;153(6):779-86. doi: 10.1016/j.surg.2013.01.001. Epub 2013 Mar 13.

13.

The role of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Deraco M, Baratti D, Hutanu I, Bertuli R, Kusamura S.

Ann Surg Oncol. 2013 Apr;20(4):1093-100. doi: 10.1245/s10434-012-2845-x. Epub 2013 Mar 2.

PMID:
23456386
14.

A novel nomogram for peritoneal mesothelioma predicts survival.

Schaub NP, Alimchandani M, Quezado M, Kalina P, Eberhardt JS, Hughes MS, Beresnev T, Hassan R, Bartlett DL, Libutti SK, Pingpank JF, Royal RE, Kammula US, Pandalai P, Phan GQ, Stojadinovic A, Rudloff U, Alexander HR, Avital I.

Ann Surg Oncol. 2013 Feb;20(2):555-61. doi: 10.1245/s10434-012-2651-5. Epub 2012 Dec 12.

PMID:
23233234
15.

Current trends in the management of malignant peritoneal mesothelioma.

Miura JT, Johnston FM, Gamblin TC, Turaga KK.

Ann Surg Oncol. 2014 Nov;21(12):3947-53. doi: 10.1245/s10434-014-3803-6. Epub 2014 May 20.

PMID:
24841356
16.

[Peritoneal mesothelioma: treatment with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy].

Passot G, Cotte E, Brigand C, Beaujard AC, Isaac S, Gilly FN, Glehen O.

J Chir (Paris). 2008 Sep-Oct;145(5):447-53. French.

PMID:
19106865
17.

Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Mesothelioma: Experience of a Peritoneal Surface Malignancy Center.

Aydin N, Sardi A, Milovanov V, Nieroda C, Sittig M, Nunez MF, Jimenez W, Gushchin V.

Am Surg. 2015 Dec;81(12):1253-9.

PMID:
26736164
18.

Body surface area predicts plasma oxaliplatin and pharmacokinetic advantage in hyperthermic intraoperative intraperitoneal chemotherapy.

Leinwand JC, Bates GE, Allendorf JD, Chabot JA, Lewin SN, Taub RN.

Ann Surg Oncol. 2013 Apr;20(4):1101-4. doi: 10.1245/s10434-012-2790-8. Epub 2013 Mar 2.

19.

Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC).

Baratti D, Kusamura S, Cabras AD, Bertulli R, Hutanu I, Deraco M.

Eur J Cancer. 2013 Oct;49(15):3140-8. doi: 10.1016/j.ejca.2013.05.027. Epub 2013 Jul 4.

PMID:
23831335
20.

Peritoneal mesothelioma after environmental asbestos exposure.

Rosenthal R, Langer I, Dalquen P, Marti WR, Oertli D.

Swiss Surg. 2003;9(6):311-4.

PMID:
14725101

Supplemental Content

Support Center